$0.00
0.00%
NYSE, Sep 16, 04:00 pm EDT.
ISIN
US14216R1014
Symbol
CARM

Carisma Therapeutics Stock price

$0.00
-0.00 69.57% 1M
-0.04 98.15% 6M
-0.04 98.37% YTD
-0.28 99.75% 1Y
-4.63 99.98% 3Y
-1.47 99.95% 5Y
-5.73 99.99% 10Y
-19.13 100.00% 20Y
NYSE, Closing price Fri, Sep 18 2026
-0.00 12.50%
ISIN
US14216R1014
Symbol
CARM
Industry

Is Carisma Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$30.0k
Enterprise Value
$-1.6m
Net debt
positive
Cash
$2.0m
Shares outstanding
41.8m
Valuation (TTM | estimate)
P/E
negative
P/S
0.0 | -
EV/Sales
negative | -
EV/FCF
0.0
P/B
0.0
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | -85.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$10.8m | $0.0
EBITDA
$-44.0m
EBIT
$-46.1m
Net Income
$-49.4m
Free Cash Flow
$-37.3m
Growth (TTM | estimate)
Revenue
-48.0% | -100.0%
EBITDA
39.3%
EBIT
39.3%
Net Income
31.9%
Free Cash Flow
51.2%
Margin
Gross
-
EBITDA
-409.1%
EBIT
-428.3%
Net
-458.6%
Free Cash Flow
-346.8%
Financial Health
Equity Ratio
-91.6%
Return on Equity
216.7%
ROCE
1,170.3%
ROIC
1,874.4%
Debt/Equity
0.0
More
EPS
$-1.2
FCF per Share
$-0.9
Short interest
3.6%
Employees
46
Rev per Employee
$430.0k

Carisma Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Carisma Therapeutics forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Carisma Therapeutics forecast:

Hold
50%
Sell
50%

Financial data from Carisma Therapeutics

Jun '25
+/-
%
11 11
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
26% 26%
171%
- Research and Development Expense 38 38
46% 46%
357%
-44 -44
39% 39%
-409%
- Depreciation and Amortization 2.07 2.07
39% 39%
19%
EBIT (Operating Income) EBIT -46 -46
39% 39%
-428%
Net Profit -49 -49
32% 32%
-458%

In millions USD.

Don't miss a Thing! We will send you all news about Carisma Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Head office United States
CEO Mr. Jalbert
Employees 46
Founded 2016
Website sesenbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today